Table 6 Outcome in patients with severe COVID-19.

From: COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Category

Infection outcome

p value

Resolution

Death

 

Untreated

190 (73.9%)

67 (26.1%)

<0.001

Continued BTKi

20 (66.7%)

10 (33.3%)

Stopped BTKi

36 (46.2%)

42 (53.8%)

  1. No statistically significant difference between continued and stopped (p = 0.08).
  2. BTKi Bruton’s tyrosine kinase inhibitor.
Back to article page